Insights - ChemoCentryx (CCXI) announced on Friday before the open that the Phase III SHIELD-1 study, testing the chemokine receptor inhibitor vercirnon in patients with moderate-to-severe Crohn’s … Continue Reading
Read NowInsights - Celsion (CLSN) has issued a glowing but arguably immaterial press release reminding investors that, yes, there is another company on earth that has a small … Continue Reading
Read NowInsights - Recent-IPO Alcobra Ltd. (ADHD) has been on a tear over the last 10 days, and while the stock has gotten away from us since we … Continue Reading
Premium: Read NowInsights - Within biotechnology and the broader healthcare sector, investor sentiment often reaches extremes. A company might be heralded as a revolution in medicine and see its … Continue Reading
Read NowInsights - Optimer Pharma (OPTR) announced that along with the ousting of upper level management and appointment of an interim CEO, it’s putting the company up for … Continue Reading
Read NowInsights - Affymax’s (AFFY) marketing partner Takeda announced weaker-than-expected sales for Omontys, Affmax’s erythropoeitin stimulating agent (ESA) for dialysis patients. Omontys was approved in the U.S. in March 2012 and is the key … Continue Reading
Read Now